Compass Therapeutics (NASDAQ:CMPX) Posts Quarterly Earnings Results, Misses Expectations By $0.01 EPS

Compass Therapeutics (NASDAQ:CMPX - Get Free Report) issued its quarterly earnings data on Thursday. The company reported ($0.11) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.10) by ($0.01), Zacks reports.

Compass Therapeutics Price Performance

Shares of CMPX stock traded down $0.17 during trading hours on Monday, hitting $2.73. The stock had a trading volume of 1,057,268 shares, compared to its average volume of 1,931,967. The stock's 50 day moving average is $2.59 and its 200 day moving average is $1.96. The firm has a market capitalization of $375.62 million, a PE ratio of -7.38 and a beta of 1.17. Compass Therapeutics has a twelve month low of $0.76 and a twelve month high of $4.08.

Wall Street Analyst Weigh In

A number of equities research analysts have issued reports on the stock. Leerink Partnrs lowered shares of Compass Therapeutics from a "strong-buy" rating to a "hold" rating in a report on Friday, November 15th. Jefferies Financial Group lifted their target price on Compass Therapeutics from $7.00 to $8.00 and gave the company a "buy" rating in a report on Monday, February 10th. HC Wainwright restated a "buy" rating and set a $10.00 price target on shares of Compass Therapeutics in a report on Wednesday, January 8th. Piper Sandler began coverage on Compass Therapeutics in a research note on Wednesday, February 19th. They issued an "overweight" rating and a $12.00 price objective for the company. Finally, Guggenheim began coverage on shares of Compass Therapeutics in a research note on Monday, February 24th. They set a "buy" rating and a $12.00 target price on the stock. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Moderate Buy" and a consensus target price of $11.38.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.